Program
ruxolitinib
Also written as “Ruxolitinib”, “Ruxolitinib cream” and “Ruxolitinib Cream”.
Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Vitiligo · Graft vs Host Disease · Pancreatic Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 689 open or running | phase 4since Jan 13, 2023 | Jul 30, 2007 | Dec 9, 2026phase 1 · NCT07049575 |
| Novartis | 214 open or running | phase 4since Mar 16, 2012 | Jul 6, 2009 | May 10, 2029phase 4 · NCT06824103 |
| Suzhou Junjing BioSciences | 11 open or running | phase 2since Mar 27, 2025 | Mar 27, 2025 | Oct 31, 2027phase 2 · NCT06909136 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Apr 18, 2014.
- Mar 7, 2024Phase 1 study in Healthy ParticipantsIncyte · NCT06310304 · 24 enrolled · United States
- Apr 25, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06388564 · 130 enrolled · United States, Belgium, Canada and more
- Jun 5, 2024Phase 4 study in Steroid-refractory Acute Graft Versus Host DiseaseNovartis · NCT06462469 · 36 enrolled · China
- Aug 8, 2024Phase 3 study in NonSegmental VitiligoIncyte · NCT06548360 · 180 planned · United States, Canada
- Aug 12, 2024Phase 1 study in Healthy ParticipantsIncyte · NCT06555081 · 168 enrolled · United States
- Sep 6, 2024Phase 3 study in Graft vs Host DiseaseIncyte · NCT06615050 · 572 planned · United States
- Jan 27, 2025Phase 3 study in NonSegmental VitiligoIncyte · NCT06804811 · 250 planned · Argentina, Austria, Belgium and more
- Feb 4, 2025Phase 3 study in Dermatitis, AtopicIncyte · NCT06832618 · 159 enrolled · United States, Belgium, Canada and more
- Feb 4, 2025Phase 4 study in Graft vs Host DiseaseNovartis · NCT06824103 · 50 planned · China
- Mar 27, 2025Suzhou Junjing BioSciences’ first study: phase 2 study in Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalyNew to Suzhou Junjing BioSciencesSuzhou Junjing BioSciences · NCT06909136 · 33 enrolled · China
- Apr 25, 20252 phase 3 studies in Hidradenitis SuppurativaIncyte · NCT06958211, NCT06959225
- Jun 25, 2025Phase 1 study in Hidradenitis SuppurativaIncyte · NCT07049575 · 24 planned · United States
- Jan 6, 2026Phase 1 study in Primary MyelofibrosisNovartis · NCT07340138 · 3 enrolled · Japan
- May 8, 2026Phase 1 study in Healthy ParticipantsIncyte · NCT07588139 · 24 enrolled · United States
Ahead
- Dec 9, 2026Primary completion: phase 1 study in Hidradenitis SuppurativaIncyte · NCT07049575
- Apr 30, 2027Primary completion: phase 3 study in NonSegmental VitiligoIncyte · NCT06804811
- Sep 30, 2027Primary completion: phase 2 study in Pancreatic NeoplasmsIncyte · NCT02955940
- Oct 31, 2027Primary completion: phase 2 study in Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalySuzhou Junjing BioSciences · NCT06909136
TargetBeta
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
The newest 60 of 90 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07588139Healthy Participants · United States | 1 | Completed | Incyte | Sep 8, 2026 | 24 |
| NCT07340138Primary Myelofibrosis · Japan | 1 | Active, not recruiting | Novartis | Jul 23, 2026 | 3 |
| NCT07049575Hidradenitis Suppurativa · United States | 1 | Recruiting | Incyte | Dec 9, 2026 | 24 |
| NCT06959225Hidradenitis Suppurativa · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | Incyte | Oct 29, 2026 | 580 |
| NCT06958211Hidradenitis Suppurativa · United States, Belgium, Bulgaria and more | 3 | Active, not recruiting | Incyte | Oct 1, 2026 | 573 |
| NCT06909136Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly · China | 2 | Active, not recruiting | Suzhou Junjing BioSciences | Oct 31, 2027 | 33 |
| NCT06832618Dermatitis, Atopic · United States, Belgium, Canada and more | 3 | Active, not recruiting | Incyte | Aug 7, 2026 | 159 |
| NCT06824103Graft vs Host Disease · China | 4 | Recruiting | Novartis | May 10, 2029 | 50 |
| NCT06804811NonSegmental Vitiligo · Argentina, Austria, Belgium and more | 3 | Recruiting | Incyte | Apr 30, 2027 | 250 |
| NCT06615050Graft vs Host Disease · United States | 3 | Recruiting | Incyte | Jan 17, 2031 | 572 |
| NCT06555081Healthy Participants · United States | 1 | Completed | Incyte | Oct 25, 2024 | 168 |
| NCT06548360NonSegmental Vitiligo · United States, Canada | 3 | Recruiting | Incyte | Jun 5, 2028 | 180 |
| NCT06462469Steroid-refractory Acute Graft Versus Host Disease · China | 4 | Active, not recruiting | Novartis | Sep 3, 2026 | 36 |
| NCT06388564Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more | 2 | Active, not recruiting | Incyte | Oct 1, 2026 | 130 |
| NCT06310304Healthy Participants · United States | 1 | Completed | Incyte | Apr 16, 2024 | 24 |
| NCT06238817Dermatitis, Atopic · United States, Australia, Belgium and more | 3 | Completed | Incyte | May 21, 2025 | 241 |
| NCT06213831Prurigo Nodularis · United States | 1 | Completed | Incyte | Jul 17, 2025 | 23 |
| NCT05906628Eczema · United States, Canada, Germany and more | 2 | Completed | Incyte | Jul 15, 2024 | 186 |
| NCT05764161Prurigo · United States, Australia, Austria and more | 3 | Completed | Incyte | Dec 30, 2024 | 190 |
| NCT05750823Vitiligo · United States, Canada, France | 2 | Completed | Incyte | Mar 6, 2025 | 49 |
| NCT05755438Prurigo · United States, Argentina, Belgium and more | 3 | Completed | Incyte | Oct 7, 2024 | 204 |
| NCT05696392Dermatitis, Atopic · United States | 4 | Terminated | Incyte | Jan 22, 2025 | 47 |
| NCT05635838Hidradenitis Suppurativa · United States, Canada | 2 | Completed | Incyte | Oct 19, 2023 | 69 |
| NCT05593445Lichen Sclerosus et Atrophicus · United States, Canada | 2 | Completed | Incyte | Sep 1, 2023 | 61 |
| NCT05593432Lichen Planus · United States, Canada | 2 | Completed | Incyte | Oct 2, 2023 | 64 |
| NCT05456529Dermatitis, Atopic · United States, Canada, Poland | 3 | Completed | Incyte | May 17, 2024 | 103 |
| NCT05247489Vitiligo · United States, Canada | 2 | Completed | Incyte | Dec 19, 2023 | 55 |
| NCT05233410Eczema · United States, Bulgaria, Canada and more | 3 | Withdrawn | Incyte | Apr 25, 2024 | 0 |
| NCT05219864Eczema · United States, Canada, Czechia and more | 3 | Withdrawn | Incyte | Apr 25, 2024 | 0 |
| NCT05127421Dermatitis, Atopic · United States | 2 | Completed | Incyte | Aug 3, 2023 | 77 |
| NCT05034822Dermatitis, Atopic · United States | 1 | Completed | Incyte | Aug 7, 2023 | 29 |
| NCT04921969Dermatitis, Atopic · United States, Canada | 3 | Completed | Incyte | May 10, 2023 | 330 |
| NCT04896385Vitiligo · United States, Canada, France | 2 | Completed | Incyte | Nov 17, 2022 | 60 |
| NCT04839380Dermatitis, Atopic · Canada | 2 | Completed | Incyte | Nov 18, 2022 | 49 |
| NCT04530344Vitiligo · United States, Bulgaria, Canada and more | 3 | Completed | Incyte | Nov 14, 2022 | 458 |
| NCT04377620COVID-19 · United States, Russian Federation | 3 | Terminated | Incyte | Feb 26, 2021 | 211 |
| NCT04362137Cytokine Release Syndrome · United States, Argentina, Brazil and more | 3 | Completed | Novartis | Oct 17, 2020 | 432 |
| NCT04057573Vitiligo · United States, Bulgaria, Canada and more | 3 | Completed | Incyte | Mar 15, 2021 | 344 |
| NCT04052425Vitiligo · United States, Bulgaria, Canada and more | 3 | Completed | Incyte | Mar 18, 2021 | 330 |
| NCT03920852Dermatitis, Atopic · United States, Canada | 1 | Completed | Incyte | Dec 26, 2019 | 41 |
| NCT03774082Graft vs Host Disease · Brazil, Canada, Czechia and more | 2 | Completed | Novartis | Feb 25, 2022 | 46 |
| NCT03745651Dermatitis, Atopic · United States, Bulgaria, Canada and more | 3 | Completed | Incyte | Nov 18, 2019 | 618 |
| NCT03745638Dermatitis, Atopic · United States, Canada, France and more | 3 | Completed | Incyte | Dec 23, 2019 | 631 |
| NCT03491215Graft vs Host Disease · Belgium, Canada, Denmark and more | 2 | Completed | Novartis | Mar 11, 2021 | 45 |
| NCT03257644Dermatitis, Atopic · United States | 1 | Completed | Incyte | Oct 7, 2020 | 70 |
| NCT03123588Myeloproliferative Disorders · United States | 2 | Terminated | Incyte | Aug 3, 2020 | 12 |
| NCT03112603Graft vs Host Disease · United States, Australia, Austria and more | 3 | Completed | Incyte | May 8, 2020 | 330 |
| NCT03099304Vitiligo · United States | 2 | Completed | Incyte | Sep 12, 2018 | 157 |
| NCT03011892Dermatitis, Atopic · United States, Canada | 2 | Completed | Incyte | Jan 10, 2018 | 307 |
| NCT02955940Pancreatic Neoplasms · United States, Poland | 2 | Active, not recruiting | Incyte | Sep 30, 2027 | 10 |
| NCT02953678Graft vs Host Disease · United States | 2 | Completed | Incyte | Jan 31, 2018 | 71 |
| NCT02966353Primary Myelofibrosis · Austria, Belgium, Bulgaria and more | 2 | Completed | Novartis | Jul 24, 2018 | 51 |
| NCT02913261Graft vs Host Disease · Australia, Austria, Bulgaria and more | 3 | Completed | Novartis | Jun 24, 2019 | 310 |
| NCT02723994Leukemia · United States, Canada, Puerto Rico | 2 | Completed | Incyte | Mar 3, 2026 | 171 |
| NCT02598297Primary Myelofibrosis · Australia, Austria, Belgium and more | 3 | Terminated | Novartis | Oct 23, 2017 | 49 |
| NCT02553330Alopecia Areata · United States | 2 | Terminated | Incyte | Oct 3, 2017 | 90 |
| NCT02386800Primary Myelofibrosis · Australia, Belgium, Bulgaria and more | 4 | Active, not recruiting | Novartis | Apr 5, 2032 | 279 |
| NCT02292446Polycythemia Vera · Austria, Belgium, Bulgaria and more | 3 | Completed | Novartis | Dec 29, 2017 | 161 |
| NCT02253277Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany | 1 | Completed | Novartis | Mar 6, 2018 | 5 |
| NCT02120417Breast Neoplasms · United States, France, Italy and more | 2 | Terminated | Incyte | Feb 2016 | 149 |
How it is read
Names in the registry
- “Ruxolitinib”, 44 entries
- “Ruxolitinib cream”, 14 entries
- “Ruxolitinib Cream”, 11 entries
- “ruxolitinib”, 6 entries
- “Ruxolitinib phosphate cream”, 4 entries
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 20 studies
- Dermatitis, Atopic, 13 studies
- Vitiligo, 9 studies
- Graft vs Host Disease, 8 studies
- Pancreatic Neoplasms, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.